BioMarin Pharmaceutical Inc. Announces European Commission Approval For VIMIZIM® (Elosulfase Alfa) For The Treatment Of Morquio A Syndrome In Patients Of All Ages
Published: Apr 28, 2014
SAN RAFAEL, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Commission has granted marketing authorization for VIMIZIM® (elosulfase alfa), the first specific treatment approved in the European Union for Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) in patients of all ages. As the first drug ever approved for Morquio A syndrome, VIMIZIM has been granted orphan drug status in the European Union, which confers ten years of market exclusivity.
Help employers find you! Check out all the jobs and post your resume.